{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:52:56Z","timestamp":1769586776690,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences (TUMS)","doi-asserted-by":"crossref","award":["27746"],"award-info":[{"award-number":["27746"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jpsychires.2017.06.011","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T19:30:18Z","timestamp":1498678218000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial"],"prefix":"10.1016","volume":"94","author":[{"given":"Ladan","family":"Kashani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazila","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-1402","authenticated-orcid":false,"given":"Ehsan","family":"Moazen-Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Ali","family":"Karkhaneh-Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Sadighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Reza","family":"Khodaie-Ardakani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Rahiminejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2017.06.011_bib1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.pnpbp.2008.08.020","article-title":"Effect of ritanserin, a 5HT2A\/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib2","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1136\/eb-2016-102500","article-title":"More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia","volume":"20","author":"Akhondzadeh","year":"2017","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.60.6.565","article-title":"Sex differences in the risk of schizophrenia: evidence from meta-analysis","volume":"60","author":"Aleman","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2004.10.002","article-title":"Gender differences in electroconvulsive therapy: a retrospective chart review","volume":"84","author":"Bloch","year":"2005","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.2007.00992.x","article-title":"Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?","volume":"115","author":"Buckley","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib7","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.psyneuen.2013.04.016","article-title":"Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats","volume":"38","author":"Caruso","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/00006842-200109000-00016","article-title":"Changes in premenstrual symptoms in women with schizophrenia: a prospective study","volume":"63","author":"Choi","year":"2001","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib9","first-page":"233","article-title":"Manual for the extrapyramidal symptom rating scale (ESRS)","volume":"7","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ajp.2015.07.016","article-title":"Contribution of sex hormones to gender differences in schizophrenia: a review","volume":"18","author":"da Silva","year":"2015","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.18553\/jmcp.2013.19.6.468","article-title":"Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients","volume":"19","author":"Desai","year":"2013","journal-title":"J.\u00a0Manag. Care Spec. Pharm."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/09540261.2012.725219","article-title":"Epidemiology of schizophrenia\u2013An update with a focus on developing countries","volume":"24","author":"Esan","year":"2012","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib13","series-title":"User's Guide for the Structured Clinical Interview for DSM-iv axis I Disorders SCID-i: Clinician Version","author":"First","year":"1997"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.yhbeh.2006.06.029","article-title":"Sex, hormones and affective arousal circuitry dysfunction in schizophrenia","volume":"50","author":"Goldstein","year":"2006","journal-title":"Horm. Behav."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/070674370204700504","article-title":"The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women","volume":"47","author":"Grigoriadis","year":"2002","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib16","first-page":"1","article-title":"Hormonal aspects of schizophrenias: an overview","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.schres.2015.04.002","article-title":"Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review","volume":"168","author":"Heringa","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.2517","article-title":"The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial","volume":"31","author":"Iranpour","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2016.05.076","article-title":"Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial","volume":"204","author":"Jafarinia","year":"2016","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10571-006-9086-0","article-title":"The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders","volume":"27","author":"MacKenzie","year":"2007","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuroscience.2011.06.076","article-title":"Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence","volume":"191","author":"Marx","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/npp.2009.26","article-title":"Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia","volume":"34","author":"Marx","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib25","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00213-014-3673-4","article-title":"Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia","volume":"231","author":"Marx","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yhbeh.2009.06.001","article-title":"Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection","volume":"57","author":"Melcangi","year":"2010","journal-title":"Horm. Behav."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0042-101557","article-title":"Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study","volume":"49","author":"Nikbakhat","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1600-0447.2000.00011.x","article-title":"Gender aspects in schizophrenia: bridging the border between social and biological psychiatry","volume":"102","author":"Riecher-R\u00f6ssler","year":"2000","journal-title":"Acta Psychiatr. Scand"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.euroneuro.2006.10.001","article-title":"Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects","volume":"17","author":"Ritsner","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1755-5949.2009.00118.x","article-title":"Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials","volume":"16","author":"Ritsner","year":"2010","journal-title":"CNS Neurosci. Ther"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuroscience.2011.04.017","article-title":"The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia","volume":"191","author":"Ritsner","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/pcn.12150","article-title":"Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial","volume":"68","author":"Ritsner","year":"2014","journal-title":"Psychiatry Clin. Neurosci"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4088\/JCP.09m05031yel","article-title":"Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial","volume":"71","author":"Ritsner","year":"2010","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"R\u00f6ssler","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A\u00a0systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib37","article-title":"Dehydroepiandrosterone for women in the peri-or postmenopausal phase","volume":"1","author":"Scheffers","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2014.12.001","article-title":"Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms","volume":"162","author":"Schooler","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0095-4543(03)00080-0","article-title":"The role of sex hormones in psychopathology: focus on schizophrenia","volume":"29","author":"Seeman","year":"2002","journal-title":"Prim. Care"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib40","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/070674370505001109","article-title":"Neuroactive steroids in schizophrenia","volume":"50","author":"Shulman","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-244X-12-193","article-title":"Disability and schizophrenia: a systematic review of experienced psychosocial difficulties","volume":"12","author":"\u015awitaj","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0000000000000159","article-title":"Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial","volume":"32","author":"Tajik-Esmaeeli","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0033291712002796","article-title":"Systematic review and collaborative recalculation of 133 693 incident cases of schizophrenia","volume":"44","author":"van der Werf","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2017.06.011_bib44","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0140-6736(14)62458-2","article-title":"Hormone therapy: short-term relief, long-term consequences","volume":"385","author":"Wentzensen","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2017.06.011_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pneurobio.2009.07.001","article-title":"Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance","volume":"89","author":"Zheng","year":"2009","journal-title":"Prog. Neurobiol."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395617300997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395617300997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T01:19:13Z","timestamp":1589764753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395617300997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":45,"alternative-id":["S0022395617300997"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.06.011","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}